Abstract
| Originalsprache | Englisch |
|---|---|
| Zeitschrift | Circulation |
| Jahrgang | 135 |
| Ausgabenummer | 24 |
| Seiten (von - bis) | 2336-2353 |
| Seitenumfang | 18 |
| ISSN | 0009-7322 |
| DOIs | |
| Publikationsstatus | Veröffentlicht - 13.06.2017 |
Fördermittel
This work was supported in part by R01-HL-111694 and K24-HL-107643 from the National Institutes of Health to Dr Reilly. PROMIS: Genotyping in PROMIS was funded by the Wellcome Trust, UK, and Pfizer. Fieldwork in the PROMIS study was supported through funds available to investigators at the Center for Non-Communicable Diseases, Pakistan, and the University of Cambridge, UK. EPIC-CVD Consortium: CHD case ascertainment and validation, genotyping, and clinical chemistry assays in EPIC-CVD were principally supported by grants awarded to the University of Cambridge from the European Union (EU) Framework Program 7 (HEALTH-F2-2012-279233), the United Kingdom (UK) Medical Research Council (G0800270) and British Heart Foundation (SP/09/002), the UK National Institute for Health Research Cambridge Biomedical Research Center, and the European Research Council (268834).
UN SDGs
Dieser Output leistet einen Beitrag zu folgendem(n) Ziel(en) für nachhaltige Entwicklung
-
SDG 3 – Gesundheit und Wohlergehen
-
SDG 5 – Gender Equality
Fingerprint
Untersuchen Sie die Forschungsthemen von „Loss of Cardioprotective Effects at the ADAMTS7 Locus as a Result of Gene-Smoking Interactions“. Zusammen bilden sie einen einzigartigen Fingerprint.Zitieren
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver